Scientific Reports (Nov 2022)

Detection of rare prostate cancer cells in human urine offers prospect of non-invasive diagnosis

  • Nima Sayyadi,
  • Irene Justiniano,
  • Yan Wang,
  • Xianlin Zheng,
  • Wei Zhang,
  • Lianmei Jiang,
  • Dmitry M. Polikarpov,
  • Robert D. Willows,
  • David Gillatt,
  • Douglas Campbell,
  • Bradley J. Walsh,
  • Jingli Yuan,
  • Yiqing Lu,
  • Nicolle H. Packer,
  • Yuling Wang,
  • James A. Piper

DOI
https://doi.org/10.1038/s41598-022-21656-9
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Two molecular cytology approaches, (i) time-gated immunoluminescence assay (TGiA) and (ii) Raman-active immunolabeling assay (RiA), have been developed to detect prostate cancer (PCa) cells in urine from five prostate cancer patients. For TGiA, PCa cells stained by a biocompatible europium chelate antibody-conjugated probe were quantitated by automated time-gated microscopy (OSAM). For RiA, PCa cells labeled by antibody-conjugated Raman probe were detected by Raman spectrometer. TGiA and RiA were first optimized by the detection of PCa cultured cells (DU145) spiked into control urine, with TGiA-OSAM showing single-cell PCa detection sensitivity, while RiA had a limit of detection of 4–10 cells/mL. Blinded analysis of each patient urine sample, using MIL-38 antibody specific for PCa cells, was performed using both assays in parallel with control urine. Both assays detected very low abundance PCa cells in patient urine (3–20 PCa cells per mL by TGiA, 4–13 cells/mL by RiA). The normalized mean of the detected PCa cells per 1 ml of urine was plotted against the clinical data including prostate specific antigen (PSA) level and Clinical Risk Assessment for each patient. Both cell detection assays showed correlation with PSA in the high risk patients but aligned with the Clinical Assessment rather than with PSA levels of the low/intermediate risk patients. Despite the limited available urine samples of PCa patients, the data presented in this proof-of-principle work is promising for the development of highly sensitive diagnostic urine tests for PCa.